The September 2026 FTSE 250 Screen: What InvestingPro Published

InvestingPro, the subscription research service from Investing.com, has published its monthly shortlist of five UK stocks for September 2026. The screen is drawn from FTSE 250-listed companies that earn a health score above 3.00 and trade below the platform’s proprietary fair-value estimates by more than 20%. The data is dated 25 August 2026.

This month’s five names are Wise, GSK, MONY Group, Intermediate Capital Group and 3i Group. It is a mixed selection: two are private-capital specialists, one is a cross-border payments fintech, one is a pharmaceutical group and one is a price-comparison business.

According to InvestingPro’s figures, Wise carries a P/E of 26.9x and no dividend; GSK trades at 15.7x with a 3.6% yield; MONY is at 12.9x with a 6.1% yield; Intermediate Capital is at 11.6x with a 4.3% yield; and 3i trades at 5.6x with a 2.9% yield. The stated potential upside ranges from roughly 27% for Wise to 69.5% for GSK.

One important caveat appears in the platform’s own data: fair value confidence is marked high for the first four names but low for 3i Group, whose 43.1% upside estimate should therefore be treated with extra care.

What the Five Picks Tell Us About the Screen's Bias

Why Wise Is the Newest Name in the Screen

Wise’s first appearance changes the character of the list. It is the only high-growth, no-dividend name, with a 26.9x P/E and a 27.6% fair-value upside. That is a growth bet on continued cross-border payment volumes, not a value or income position. Its inclusion alongside lower-P/E, dividend-paying names suggests the screener is combining quality, value and growth factors rather than applying a single style.

Where the “Undervalued” Label Comes From

The headline upside figures are not market forecasts. They are the percentage difference between each company’s current price and InvestingPro’s own fair-value estimate, produced from five overlaid models. That is why GSK can show a 69.5% upside while trading at a modest 15.7x P/E. These are model outputs, and the platform’s own low-confidence flag for 3i shows the estimates are stronger for some names than others.

What the Dividend and Valuation Spread Actually Shows

The five names span a wide risk-return spectrum. MONY’s 6.1% yield and 12.9x P/E look attractive for income, but a small-cap high yield can also signal market concern about whether the dividend is fully covered. Intermediate Capital’s 4.3% yield and 3i’s 5.6x P/E reflect private-market asset exposure, which can be volatile when portfolio valuations change. GSK’s 3.6% yield is the most defensive part of the screen, but its upside estimate relies heavily on pipeline execution.

The Monthly Screen’s Persistence Problem

Several names recur across InvestingPro’s previous monthly tables—3i Group and GSK appear repeatedly, and Morgan Sindall is a regular in earlier lists. That persistence is not necessarily a fresh market signal: it reflects the screen’s stable factor characteristics and continuing valuation rankings. A name staying on the list for several months is different from a new signal that the market has mispriced it.

A DIY Investor's Checklist for the September List

For investors using this monthly list as a starting point, the useful step is to test the screen’s inputs rather than take the upside figures at face value.

  • Re-price each name as of today. The screen was built on 25 August 2026 data, so Wise at 26.9x P/E, GSK at 15.7x and MONY at 12.9x may already be stale; update prices before comparing any upside to the stated fair value.
  • Check MONY’s 6.1% dividend against free cash flow and payout history. The yield is the highest in the list, but income only matters if the payout is covered and sustainable after capital spending.
  • Treat 3i’s 43.1% upside and GSK’s 69.5% upside as model outputs, not expected returns. For 3i, the platform’s own fair-value confidence is low, so recalculate using your own book-value or earnings assumptions.
  • Watch the events the screen does not capture. GSK’s oncology and HIV pipeline news, Wise’s cross-border volume reports and private-capital portfolio revaluations at Intermediate Capital and 3i can move prices more than a health score.